Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotic Formula vs Rifaximin for SIBO in IBS
NCT04316806Terminated
- Sponsor
- AB-BIOTICS
- Start
- Nov 2020
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Randomised, open-label trial in irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO) (2 arms), sponsored by AB-BIOTICS. Primary endpoint: Small Intestinal Bacterial Overgrowth Status at 4 weeks. Started Nov 2020; status: terminated.
02
Conditions
irritable bowel syndrome (IBS)small intestinal bacterial overgrowth (SIBO)
Beyond the preview
Go deeper on NCT04316806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04316806.